Výpis publikací

ČULEN, Martin, Daniel BUŠA, Zdeňka HERUDKOVÁ, Jan HÝL, Jakub VLAŽNÝ, Květoslava MATULOVÁ, Martin REPKO, Lucy VOJTOVÁ a Jiří MAYER. AML engraftment in humanized ossicles is not governed by biomaterial selection. In ESH: 4th Scientific Workshop: the Haematological Tumour Microenvironment and its Therapeutic Targeting, UK, Londýn. 2023.

ČULEN, Martin, Tomáš LOJA, Daniel BUŠA, Zdeňka HERUDKOVÁ, Jan HÝL, Jakub VLAŽNÝ, K. LIŠKOVÁ, Martin REPKO, Lucy VOJTOVÁ a Jiří MAYER. Biomaterial selection does not affect AML engraftment in humanized ossicles. In 12th International Conference Analytical Cytometry, Praha. 2023.

HÝL, Jan, Veronika BUČKOVÁ, Tereza SLAMĚNÍKOVÁ a Martin ČULEN. Effect of media components and feeder cells on in vitro culture of acute myeloid leukemia. In ESH: 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, Estoril, Portugalsko. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.